New Jersey's Premier Heart Transplant Program
The Barnabas Health Heart Failure and Transplant program is the most experienced
and comprehensive center in New Jersey. It has been at the forefront of
highly specialized care for more than twenty years. Our cardiac surgeons
and heart specialists' expertise has made RWJBarnabas Health a regional
and national training center for physicians, nurses and emergency services
Dr. Joseph Clemente, host of MHC-TV, interviews Mark J. Zucker, M.D., J.D.,
Director, Heart Failure Treatment and Transplant Program at Newark Beth
Isreal Medical Center. They discuss getting a heart transplant, other
treatments such as the Left Ventricular Assist Device (LVAD), and about
stem cell research ongoing today.
Learn about CardioMEMS, a new treatment for heart failure
Barnabas Health Heart Centers Earn Recognition from American Heart Association
in Heart Failure Treatment
The Barnabas Health Heart Centers provide progressive heart failure management
that optimizes the patient's transition to home and empowers them
to improve their heart health. Advanced practice nurses contact patients
within days of discharge and facilitate daily medical monitoring, education,
and counseling. Patient-centered programs bring together all the medical
resources necessary to combat heart failure and the reduction in hospital
readmission rates has been significant. Heart failure clinics are based
at all Barnabas Health hospitals.
Clinical trials provide patients with access for breakthrough medications,
devices, and therapies, while being continually monitored and evaluated.
Our participation in new cardiac stem cell research for patients with
refractory angina and chronic myocardial ischemia may someday help the
heart heal itself. Improved technology has made positive outcomes with
ECMO more likely both at our center and nationally, and has resulted in
increased referrals for this critical care.
Our heart transplant program is the third largest in the nation with survival
rates that consistently meet or exceed national benchmarks. The center
is at the forefront of improving the quality of life for transplant candidates
and recipients, as well as increasing access to transplant. Our unique
work in establishing successful protocols for discontinuing steroid medications
for immunosuppression is improving the medical management and survival
rates for transplant recipients worldwide. Noninvasive gene expression
testing offers an alternative technique for assessing immunosuppression
and predicting rejection. The center is also part of groundbreaking research
that is exploring innovating methods for preserving donor organs for transplant.
Ventricular Assist Devices (VADs)
Implantable VADs are placed for myocardial recovery, bridge to transplant,
and destination therapy. Because the VAD program is totally integrated
with heart failure and transplant services, patients are thoroughly and
continually evaluated for all treatment options. The heart transplant
center's experience has made it a principal site for clinical research
trials of the latest generation of mechanical assist devices and a regional
VAD transplantation training site. With virtually all FDA-approved and
investigational implantable devices available, patients receive the device
that meets their individual needs.